Happy summer and welcome to the newsletter from LUNGevity's EGFR Patient Gateway.
Not only is it hot outside, but there are a lot of hot topics in EGFR+ non-small cell lung cancer (NSCLC) these days.
In this edition of the newsletter, we highlight articles discussing advances in developing new EGFR targeted therapies against both classic and more "atypical" mutations. We also include information on EGFR exon 20 insertion mutation, which historically has been more difficult to treat than the more classic EGFR mutations.
One of the hottest topics right now relates to biomarker testing and the use of targeted therapy for patients with early-stage EGFR+ NSCLC. We also include articles describing histological transformation of EGFR+ NSCLC, meaning over time, the NSCLC can turn into SCLC. Another challenge of targeted therapy is managing adverse events from treatment, which is discussed in one of the articles. Finally, the prevalence of EGFR varies depending on where people are from, with a higher incidence of this mutation in the Asian population compared to other parts of the world.
We hope you enjoy learning about these developments related to diagnosis and treatment of EGFR+ NSCLC.
Research News
BioSpace
ASCO: AstraZeneca Posts Strong Survival Data for Tagrisso in NSCLC Patients
Published June 5, 2023
OncLive
Continued Emergence of Targeted Therapies for EGFR-Mutant NSCLC Underscores Importance of Molecular Testing
Published July 27, 2023
OncLive
Routine Molecular Testing in Early NSCLC Post-Resection
Published July 24, 2023
Journal of Clinical Oncology
Zipalertinib in EGFR Exon 20–Mutant Non–Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting
Published July 24, 2023
Science Direct
Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
Published July 8, 2023
Cancer Health
Tagrisso After Lung Cancer Surgery Cuts Risk of Death by Half
Published June 5, 2023
OncLive
Dr Santos on the Evolution of Osimertinib in EGFR Mutated NSCLC
Published May 31, 2023
NewsBeezer
Strategies for managing osimertinib adverse events in EGFR+ NSCLC
Published May 17, 2023
HMP
EGFR Mutation Prevalence in Non-Small Cell Lung Cancer in West-European Patient Population
Published March 9, 2023
Get Connected
Join us for the EGFR Virtual Meetup
It’s the easy way to build your community. The first Wednesday of each month, you can connect with others who understand what it’s like to live with EGFR+ lung cancer. The next EGFR Virtual Meetup is happening on Wednesday, September 6, 2023, at 12pm ET. Register for the EGFR Meetup to get a confirmation email with details about how to join the virtual meeting.
Register for the ILCSC (September 22-23, 2023)
The International Lung Cancer Survivorship Conference is LUNGevity’s annual conference (held virtually) to inform patients and caregivers about the latest lung cancer research and treatments. The popular session dedicated to EGFR+ lung cancer is back again this year. Learn more about this free conference and the world-renowned researchers who will be speaking.
Have You Seen?
EGFR+ Lung Cancer: Going Beyond Osimertinib
In this webinar, join patient advocates and EGFR Resisters co-founders Ivy Elkins and Jill Feldman as they discuss what’s next once osimertinib stops working in patients with EGFR+ lung cancer. Panelists also include renowned physician-scientists Drs. Christine Lovly and Helena Yu. Watch it here.
Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer
In this article, we learn about an important study published in Nature that suggests some types of air pollution may trigger the development of lung cancer in people with EGFR mutations. This finding opens new avenues for understanding lung cancer’s origins and suggests there may be ways to help prevent the disease from developing in the first place. Read it here.
Let Your Voice Be Heard
We are collecting stories from patients, caregivers, friends, and family members to help us better understand the challenges and triumphs of lung cancer. Tell us how lung cancer has affected your life: How was the lung cancer diagnosed? Do you have any tips for communicating your needs to friends and family? Has lung cancer caused extra financial pressures? Any information you provide will only be used to improve LUNGevity’s programs and initiatives. Email your story to us at support@lungevity.org and let us know if you’d be willing to chat with a LUNGevity staff member or if you’d like your story to be featured on the EGFR Patient Gateway.
Fuel for the Future: Good Nutrition for the Lung Cancer Community
Learn valuable information about good nutrition that can help you live well through lung cancer treatment and beyond. Gain insight and tips from oncology dietitian Lori Bumbaco, MS, RDN, CSO, as she shares her expertise in an interactive presentation and answers nutrition questions from the community. Then watch a live cooking demo, where Lori prepares a healthy meal and snack and shares recipe ideas and cooking tips. Watch it here.
…and so much more at the EGFR Patient Gateway.
If you were forwarded this email and you’d like to subscribe to this newsletter, you can sign up here.
If you need further assistance, please email us at support@lungevity.org. Our team is always here to assist you.
